1. Home
  2. Advocacy
  3. Latest News and Practice Data
  4. FDA Discusses Registration and Listing Rules for LDTs

FDA Discusses Registration and Listing Rules for LDTs

Dec 10, 2024

On December 3, the FDA led a webinar reviewing compliance for its registration and device listing requirements for laboratory-developed tests (LDTs). These requirements are part of stage 2 of the FDA LDT oversight regulation and take effect May 2026. Stage 1 requirements take effect May 6, 2025.

The CAP had previously urged the FDA to provide more education about the agency’s process for registration and listing how the process would apply to LDTs.

Review the FDA webinar slides and webpage.

Most Recent Content

  1. October 14, 2025
    Advocacy Updates Advocacy Updates
    Oct 14, 2025
  2. CAP opposes gene patent bill, citing harms to health care and innovation
    Advocacy Updates Advocacy Updates
    Oct 14, 2025
  3. Ongoing government shutdown hits FDA, CDC staffing, programs
    Advocacy Updates Advocacy Updates
    Oct 14, 2025
  4. CAP board appoints Akshay Patel as interim CEO starting later this month
    Advocacy Updates Advocacy Updates
    Oct 14, 2025
  5. Online media training sessions planned in November, December
    Advocacy Updates Advocacy Updates
    Oct 14, 2025
  6. View All
To Top